home / stock / drmaw / drmaw quote
Last: | $0.0095 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0092 |
Close: | $0.0095 |
High: | $0.0095 |
Low: | $0.0082 |
Volume: | 3,026 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.0095 | $0.0092 | $0.0095 | $0.0095 | $0.0082 | 3,026 | 04-25-2024 |
$0.0092 | $0.0092 | $0.0092 | $0.0092 | $0.0092 | 1,000 | 04-24-2024 |
$0.0092 | $0.01 | $0.0092 | $0.01 | $0.009 | 8,810 | 04-11-2024 |
$0.014 | $0.0141 | $0.014 | $0.0141 | $0.014 | 27,718 | 04-10-2024 |
$0.014 | $0.014 | $0.014 | $0.014 | $0.014 | 22,181 | 04-05-2024 |
$0.01022 | $0 | $0.01022 | $0 | $0 | 20 | 04-04-2024 |
$0.01022 | $0.0097 | $0.01022 | $0.01022 | $0.0097 | 6,001 | 04-03-2024 |
$0.0095 | $0.011 | $0.0095 | $0.011 | $0.0092 | 39,019 | 03-27-2024 |
$0.011 | $0.0114 | $0.011 | $0.0147 | $0.011 | 2,124 | 03-25-2024 |
$0.0114 | $0.0114 | $0.0114 | $0.01465 | $0.0114 | 19,669 | 03-22-2024 |
$0.0112 | $0.011301 | $0.0112 | $0.011301 | $0.0112 | 500 | 03-15-2024 |
$0.011 | $0.011 | $0.011 | $0.011 | $0.011 | 3,158 | 03-14-2024 |
$0.01 | $0.01 | $0.01 | $0.0179 | $0.009649 | 27,090 | 03-12-2024 |
$0.0093 | $0.0092 | $0.0093 | $0.0093 | $0.0092 | 5,115 | 03-07-2024 |
$0.0092 | $0.0107 | $0.0092 | $0.0107 | $0.009 | 15,115 | 03-06-2024 |
$0.0105 | $0.0195 | $0.0105 | $0.0195 | $0.0102 | 4,145 | 03-05-2024 |
$0.0105 | $0.017 | $0.0105 | $0.0185 | $0.01 | 44,478 | 03-04-2024 |
$0.0179 | $0.02 | $0.0179 | $0.02 | $0.0179 | 4,002 | 03-01-2024 |
$0.0158 | $0.0158 | $0.0158 | $0.0158 | $0.0158 | 749 | 02-29-2024 |
$0.0157 | $0.02 | $0.0157 | $0.02 | $0.0157 | 779 | 02-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Warrant Company Name:
DRMAW Stock Symbol:
NASDAQ Market:
Dermata Therapeutics, Inc. (NASDAQ: DRMAW) shares are trading higher in Thursday's after-hours session after the company announced the issuanc...
- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company is currently discussing partnership opportunities to advance development of DMT410 - - In 2022, the Japanese prevalence of hyperhid...
- About 550 patients will be treated once weekly for 12 weeks - - STAR-1 topline results expected in first quarter of 2025 - - Acne affects about 50 million patients in the U.S. - SAN DIEGO, CA / ACCESSWIRE / December 20, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Der...